MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

BioNTech SE ADR

Atidarymo kaina

SektoriusSveikatos priežiūra

105.31 -9.07

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

113

Max

120.45

Pagrindiniai rodikliai

By Trading Economics

Pajamos

143M

301M

Pardavimai

-55M

1.2B

Pelnas, tenkantis vienai akcijai

1.08

Pelno marža

25.311

Darbuotojai

6,772

EBITDA

253M

464M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+22.03% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-05-05

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-1.6B

24B

Ankstesnė atidarymo kaina

114.38

Ankstesnė uždarymo kaina

105.31

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

BioNTech SE ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-02-04 18:52; UTC

Pagrindinės rinkos jėgos

Psychedelic Drug Stocks Up, Vaccine Shares Down After Senate Committee Advances RFK Jr.

2024-11-15 10:28; UTC

Pagrindinės rinkos jėgos

European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department

2024-05-06 11:27; UTC

Uždarbis

BioNTech Swings to Net Loss on Lower Covid Vaccine Sales

2024-11-15 11:14; UTC

Rinkos pokalbiai

U.S. Vaccine Stocks Fall After Trump Picks Vaccine Skeptic RFK Jr as Health Department Head-- Market Talk

2024-11-15 10:34; UTC

Rinkos pokalbiai

Vaccine Sector Sell-Off Looks Overdone -- Market Talk

2024-08-05 10:02; UTC

Uždarbis

BioNTech Sees 2024 R&D Expenses EUR2.4B-EUR2.6B >BNTX

2024-08-05 10:01; UTC

Uždarbis

BioNTech Backs 2024 View of Rev EUR2.5B-EUR3.1B >BNTX

2024-08-05 10:01; UTC

Uždarbis

BioNTech: Invested EUR525.6M, or About 90% of 2Q R&D Spend, in Non-Covid-19 Related Activities >BNTX

2024-08-05 10:00; UTC

Uždarbis

BioNTech 2Q-End Cash, Equivalents, Security Investments EUR18.5 Billion >BNTX

2024-08-05 09:59; UTC

Uždarbis

BioNTech 2Q Loss EUR807.8M >BNTX

2024-08-05 09:59; UTC

Uždarbis

BioNTech 2Q Loss/Shr EUR3.36 >BNTX

2024-08-05 09:59; UTC

Uždarbis

BioNTech 2Q Rev EUR128.7M >BNTX

2024-05-06 20:15; UTC

Uždarbis

BioNTech Lifts As Covid Sales Plummet With 90% Of Revenue Still To Come -- IBD

2024-05-06 10:47; UTC

Uždarbis

BioNTech Sees FY24 Rev EUR2.5B-EUR3.1B >BNTX

2024-05-06 10:46; UTC

Uždarbis

Correct: BioNTech 1Q Loss/Shr EUR1.31 >BNTX

2024-05-06 10:46; UTC

Uždarbis

Correct: BioNTech 1Q Loss EUR315.1M >BNTX

2024-05-06 10:46; UTC

Uždarbis

Correct: BioNTech 1Q Rev EUR187.6M >BNTX

2024-05-06 10:45; UTC

Uždarbis

BioNTech 1Q Rev $187.6M >BNTX

2024-05-06 10:45; UTC

Uždarbis

BioNTech 1Q Loss $315.1M >BNTX

2024-05-06 10:45; UTC

Uždarbis

BioNTech 1Q Loss/Shr $1.31 >BNTX

Akcijų palyginimas

Kainos pokytis

BioNTech SE ADR Prognozė

Kainos tikslas

By TipRanks

22.03% į viršų

12 mėnesių prognozė

Vidutinis 140.13 USD  22.03%

Aukščiausias 171 USD

Žemiausias 110 USD

Remiantis 17 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines BioNTech SE ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

17 ratings

14

Pirkti

3

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

99 / N/APalaikymas ir pasipriešinimas

Trumpalaikis periodas

Bullish Evidence

Vidutinės trukmės periodas

Weak Bullish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę BioNTech SE ADR

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac